News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
539,355 Results
Type
Article (36885)
Company Profile (76)
Press Release (502386)
Multimedia
Podcasts (65)
Webinars (14)
Section
Business (146685)
Career Advice (2395)
Deals (26738)
Drug Delivery (104)
Drug Development (70705)
Employer Resources (135)
FDA (13290)
Job Trends (11656)
News (261960)
Policy (25925)
Tag
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (2)
Academia (2423)
Accelerated approval (30)
Adcomms (29)
Allergies (127)
Alliances (36544)
ALS (160)
Alzheimer's disease (1631)
Antibody-drug conjugate (ADC) (292)
Approvals (13512)
Artificial intelligence (451)
Autoimmune disease (129)
Automation (33)
Bankruptcy (302)
Best Places to Work (9515)
BIOSECURE Act (15)
Biosimilars (165)
Biotechnology (57)
Bladder cancer (149)
Brain cancer (53)
Breast cancer (581)
Cancer (4368)
Cardiovascular disease (388)
Career advice (2029)
Career pathing (36)
CAR-T (242)
CDC (39)
Cell therapy (656)
Cervical cancer (27)
Clinical research (60853)
Collaboration (1374)
Company closure (4)
Compensation (483)
Complete response letters (56)
COVID-19 (2470)
CRISPR (76)
C-suite (833)
Cystic fibrosis (114)
Data (5785)
Decentralized trials (2)
Denatured (10)
Depression (139)
Diabetes (465)
Diagnostics (5779)
Digital health (34)
Diversity (8)
Diversity, equity & inclusion (39)
Drug discovery (205)
Drug pricing (166)
Drug shortages (24)
Duchenne muscular dystrophy (219)
Earnings (56233)
Editorial (53)
Employer branding (17)
Employer resources (126)
Events (74459)
Executive appointments (958)
FDA (16052)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (10)
Frontotemporal dementia (21)
Funding (1204)
Gene editing (166)
Generative AI (39)
Gene therapy (564)
GLP-1 (920)
Government (4199)
Grass and pollen (7)
Guidances (376)
Healthcare (15380)
HIV (52)
Huntington's disease (41)
IgA nephropathy (80)
Immunology and inflammation (248)
Immuno-oncology (47)
Indications (92)
Infectious disease (2708)
Inflammatory bowel disease (171)
Inflation Reduction Act (13)
Influenza (94)
Intellectual property (219)
Interviews (521)
IPO (12134)
IRA (47)
Job creations (2428)
Job search strategy (1636)
JPM (54)
Kidney cancer (17)
Labor market (54)
Layoffs (484)
Leadership (36)
Legal (5414)
Liver cancer (88)
Longevity (10)
Lung cancer (628)
Lymphoma (348)
Machine learning (32)
Management (51)
Manufacturing (635)
MASH (173)
Medical device (10486)
Medtech (10528)
Mergers & acquisitions (15516)
Metabolic disorders (1193)
Multiple sclerosis (145)
NASH (22)
Neurodegenerative disease (303)
Neuropsychiatric disorders (92)
Neuroscience (2798)
Neurotech (1)
NextGen: Class of 2026 (5223)
Non-profit (3818)
Now hiring (53)
Obesity (544)
Opinion (256)
Ovarian cancer (146)
Pain (185)
Pancreatic cancer (202)
Parkinson's disease (263)
Partnered (28)
Patents (441)
Patient recruitment (439)
Peanut (46)
People (50729)
Pharmaceutical (19)
Pharmacy benefit managers (17)
Phase 1 (18735)
Phase 2 (26784)
Phase 3 (20452)
Pipeline (4745)
Policy (257)
Postmarket research (2198)
Preclinical (7549)
Press Release (53)
Prostate cancer (215)
Psychedelics (54)
Radiopharmaceuticals (234)
Rare diseases (762)
Real estate (3839)
Recruiting (53)
Regulatory (20246)
Reports (30)
Research institute (2041)
Resumes & cover letters (345)
Rett syndrome (25)
RNA editing (15)
RSV (66)
Schizophrenia (148)
Series A (203)
Series B (151)
Service/supplier (2)
Sickle cell disease (90)
Special edition (17)
Spinal muscular atrophy (153)
Sponsored (35)
Startups (2572)
State (2)
Stomach cancer (18)
Supply chain (85)
Tariffs (71)
The Weekly (54)
Vaccines (872)
Venture capital (75)
Weight loss (361)
Women's health (66)
Worklife (19)
Date
Last 7 days (484)
Last 30 days (1781)
Last 365 days (25263)
2026 (2365)
2025 (25612)
2024 (29329)
2023 (33022)
2022 (43267)
2021 (46247)
2020 (44752)
2019 (38059)
2018 (28838)
2017 (25866)
2016 (24457)
2015 (28631)
2014 (21271)
2013 (17137)
2012 (18309)
2011 (19389)
2010 (17120)
Location
Africa (695)
Alabama (74)
Alaska (4)
Arizona (200)
Arkansas (11)
Asia (33459)
Australia (7057)
California (8818)
Canada (2870)
China (985)
Colorado (368)
Connecticut (362)
Delaware (305)
Europe (74529)
Florida (1445)
Georgia (289)
Hawaii (1)
Idaho (47)
Illinois (704)
India (56)
Indiana (427)
Iowa (17)
Japan (376)
Kansas (105)
Kentucky (28)
Louisiana (23)
Maine (57)
Maryland (1173)
Massachusetts (6000)
Michigan (273)
Minnesota (465)
Mississippi (4)
Missouri (115)
Montana (23)
Nebraska (24)
Nevada (106)
New Hampshire (71)
New Jersey (2577)
New Mexico (21)
New York (2400)
North Carolina (1117)
North Dakota (6)
Northern California (4260)
Ohio (260)
Oklahoma (10)
Oregon (26)
Pennsylvania (1809)
Puerto Rico (22)
Rhode Island (35)
South America (947)
South Carolina (59)
South Dakota (1)
Southern California (3530)
Tennessee (138)
Texas (1447)
United States (31706)
Utah (285)
Vermont (1)
Virginia (224)
Washington D.C. (64)
Washington State (746)
West Virginia (4)
Wisconsin (78)
Wyoming (2)
539,355 Results for "gemvax as".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
GemVax Announces Topline Results from Phase 2a Progressive Supranuclear Palsy Clinical Trial at Neuro2024
October 29, 2024
·
8 min read
Obesity
AstraZeneca’s China Trip Yields CSPC Obesity Deal Worth $1.2B Upfront
The pact, which could see AstraZeneca ultimately put out $18.5 billion in milestones and sales-based payments, is centered on SYH2082, a long-acting dual agonist of the GLP-1 and GIP receptors.
January 30, 2026
·
2 min read
·
Tristan Manalac
Insights
Biotech’s Next Chapter: Asset-Centric Deals and Shifting Alpha at JPM 2026
After years of contraction, investors see biotech reentering a growth cycle driven by scientific progress, asset quality and renewed conviction in oncology, obesity and neuroscience innovation.
January 29, 2026
·
3 min read
·
Jennifer Smith-Parker
China
AstraZeneca Pledges $15B More in Chinese Investments for Cell Therapies, Radiopharma
AstraZeneca has risen as one of pharma’s most prolific investors in China, including a $630 million pledge last week for full rights to AbelZeta’s cell therapy for cancer.
January 29, 2026
·
1 min read
·
Tristan Manalac
CAR-T
AstraZeneca Pays $630M for Complete Global Rights Over AbelZeta’s CAR T
The arrangement will boost AstraZeneca’s cell therapy portfolio as the pharma targets $80 billion in revenue by 2030.
January 20, 2026
·
2 min read
·
Tristan Manalac
Business
JPM26: AstraZeneca’s Path to $80B by 2030 Paved With ADCs, Cell Therapies, Near-Term Launches
AstraZeneca is relying on several upcoming products to help hit its target of $80 billion in revenue by 2030, including drugs for hypertension, breast cancer and generalized myasthenia gravis, all of which are currently under FDA review.
January 14, 2026
·
2 min read
·
Tristan Manalac
Immunology and inflammation
J&J Stops Mid-stage Eczema Trial as $1.25B Asset Misses Efficacy Mark
J&J paid Numab Therapeutics $1.25 billion upfront for the asset in 2024 based on the belief that its dual mechanism of action could improve on existing therapies.
January 5, 2026
·
2 min read
·
Nick Paul Taylor
Drug Development
GemVax & KAEL reports further positive data from GV1001 Phase II Alzheimer’s Disease trial
GemVax & KAEL Co., Ltd. a clinical stage company developing a novel peptide drug based on telomerase modification has released further positive data at the Korean Dementia Association’s Fall Conference from a Phase II trial in Alzheimer’s disease of lead candidate GV1001
November 23, 2020
·
2 min read
Lung cancer
AstraZeneca’s ATR Inhibitor Fails To Improve Survival in Phase III Lung Cancer Trial
Ceralasertib is part of AstraZeneca’s ambitious plan to hit $80 billion in revenue by 2030.
December 22, 2025
·
1 min read
·
Annalee Armstrong
Drug Development
GemVax’s highly promising Phase II Alzheimer’s disease clinical trial results targeting telomerase published in prestigious Alzheimer’s Research & Therapy’ journal
GemVax & KAEL Co., Ltd. has announced that a paper on GV1001, a novel Alzheimer’s treatment based on telomerase modification, was published on March 26th in the SCI-grade international journal ‘Alzheimer’s Research & Therapy’.
March 30, 2021
·
2 min read
1 of 53,936
Next
